Drug Trial Radar · NCT07402876
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2027
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Conditions
- Primary Vitreoretinal Lymphoma
Interventions
ICM ADX-2191 injectionDrug
Following the development of lymphomatous vitreous cells in at least one eye, subjects will follow ICM dosing with ADX-2191 intravitreal injections twice weekly for four weeks, followed by weekly for eight weeks, for a total of sixteen injections.
Monthly ADX-2191 injectionDrug
Following the development of lymphomatous vitreous cells in at least one eye, subjects will dose monthly with ADX-2191 intravitreal injections for a total of three injections. Sham injections will be performed for those visits during which ADX-2191 is not injected, for a total of thirteen sham injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatmentTime frame: Eight weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bascom Palmer Eye Institute
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.